

Scientific program

Thursday, 12 February 2004

09.00–09.45	Opening Ceremony <i>Chair:</i> Frank Meyskens, Orange, CA/USA Hans-J rg Senn, St. Gallen/Switzerland	
09.00	Welcome from the Organizers & St. Gallen Oncology Conferences Hans-J rg Senn, St. Gallen/Switzerland	
	Welcome on Behalf of the European School of Oncology (ESO) Milano Alberto Costa, Pavia/Italy	
	Welcome on Behalf of the International Society of Cancer Chemoprevention (ISCaC) Frank Meyskens, Orange, CA/USA	
09.45–10.30	Session 1 Public Health and Medical Approaches to Cancer Prevention Lifestyle and Medical Approaches to Cancer Prevention Peter Greenwald, NCI, Bethesda, MD/USA	S1
10.30–11.00	<i>Coffee break, Posters I, Exhibition</i>	
11.00–12.30	Session 2 Onco-Genetics and Cancer Prevention – Defining Risk Groups <i>Chair:</i> Bruce Ponder, Cambridge/UK Hj. M ller, Basel/CH	
11.00	Application of Genetics to the Prevention of Colorectal Cancer John Hopper, Carlton, Victoria/AUS	S2
11.20	Genetics and Prevention in Relation to Oesophageal Adenocarcinoma Rebecca Fitzgerald, Cambridge/UK	S3
11.40	Fitting Steroid Hormones into a Risk Algorithm for Breast Cancer Mitch Dowsett, London/UK	S4
12.00–12.30	Discussion and Critical Session Review (B. Ponder)	
12.30–14.00	<i>Lunch, Posters, Exhibition</i>	

14.00–15.30	Session 3 <i>Preclinical Models with Relevance to Clinical Cancer Prevention</i> <i>Chair:</i> Michael Pollak, Montreal/Canada Friedrich Marks, Heidelberg/Germany	
14.00	Preclinical Models Relevant to Diet, Exercise and Cancer Risk J. Barnard, Los Angeles, CA/USA	S5
14.20	Models of Hormonal Manipulation as a Strategy for Cancer Risk Reduction for Specific Classes of At-Risk Individuals Michael Pollak, Montreal/Canada	S6
14.40	Can Laboratory Studies Help in Selecting Specific Compounds for Prevention Trials? Ernest Hawk, Bethesda, MD/USA	S7
15.00–15.30	Discussion and Critical Session Review (M. Pollak)	
15.30–16.00	<i>Coffee Break, Posters, Exhibition</i>	
16.00–17.30	Session 4 <i>Problems and Promise of Surrogate Markers in Tumor Prevention</i> <i>Chair:</i> Frank Meyskens, Irvine, CA/USA Arthur Schatzkin, Rockville, MD/USA	
16.00	Problems with Using Biomarkers as Surrogates Arthur Schatzkin, Rockville, MD/USA	S8
16.15	Can a Marker be a Surrogate for Development of Cancer and Would We Know it if it Existed? William Armstrong, Irvine, CA/USA	S9
16.35	Karyometry as an Integrating Biomarker Dean E. Brenner, Ann Arbor, MI/USA	S10
16.55	How Should We Try to Move the Field Forward? Frank Meyskens, Irvine, CA/USA	S11
17.10–17.30	Discussion and Critical Session Review (A. Schatzkin)	
17.30	Welcome Reception (with musical entertainment), University Foyer	
19.00	Official Speakers' Dinner (by invitation) Restaurant Schliessli zum Spisertor Free evening for participants; evening shopping in St. Gallen until 21.00 h	

Friday, 13 February 2004

09.00–10.30	Session 5 <i>Primary Prevention of Breast Cancer I: Ovarian Suppression and Ablation in Premenopausal Women at Risk</i> <i>Chair:</i> Alberto Costa, Pavia/Italy Trevor Powles, Sutton, Surrey/UK	
09.00	The Problems of Risk Selection: Scientific and Psychosocial Aspects Anne-Renee Hartman, Boston, MA/USA	S12
09.25	Prophylactic Mastectomy or Pharmacologic Prevention Jan Klijn, Rotterdam/NL	S13
09.45	Temporary Ovarian Suppression in Premenopausal Women at Risk of Breast Cancer Anthony Howell, Manchester/UK	S14
10.05	Discussion and Critical Session Review (T. Powles)	
10.30–11.00	<i>Coffee Break, Posters, Exhibition</i>	
11.00–12.30	Session 6 <i>Primary Prevention of Breast Cancer II: Update of Chemoprevention with Tamoxifen, Raloxifen and Aromatase-Inhibitors</i> <i>Chair:</i> Anthony Howell, Manchester/UK Jack Cuzick, London/UK	
11.00	The US Breast Cancer-Prevention Trials (NSABP-P1, MORE, STAR) Victor Vogel, Pittsburgh, PA/USA	S15
11.20	Is Low-Dose Tamoxifen a Reasonable Alternative? Andrea Decensi, Milano/Italy	S16
11.40	Aromatase Inhibitors in Breast Cancer Prevention: IBIS-Trial II Jack Cuzick, London/UK	S17
12.00	Breast Cancer Chemoprevention: Quo Vadis? Trevor Powles, Sutton, Surrey/UK	S18
12.15	Discussion and Critical Session Review (J. Cuzick)	
12.30–14.00	<i>Lunch, Posters, Exhibition</i>	
12.30–14.00	<i>ISCaC Board Meeting</i> (Room to be announced)	

14.00–15.30	Session 7 <i>Prevention and Early Detection of Lung Cancer</i> <i>Chair:</i> Thomas Cerny, St. Gallen/Switzerland Triantafillos Liloglou, Liverpool/UK	
14.00	Molecular Markers in Early Detection of Lung Cancer Triantafillos Liloglou, Liverpool/UK	S19
14.20	Chemoprevention Studies in Lung Cancer Jean-Charles Soria, Villejuif/France	S20
14.40	Early Detection of Lung Cancer by CT-Screening Karl Klingler, Zurich/Switzerland	S21
15.00	Anti-Nicotine Vaccination: Where Are We? Thomas Cerny, St. Gallen/Switzerland	S22
15.15–15.30	Discussion and Critical Session Review (Th. Cerny)	
15.30–16.00	<i>Coffee Break, Posters, Exhibition</i>	
16.00–17.30	Session 8 <i>Prevention of Colorectal Cancer: Where are we Going?</i> <i>Chair:</i> Bernard Levin, Houston, TX/USA Werner Schwizer, St. Gallen/CH	
16.00	Primary Prevention of Colorectal Cancer: Lifestyle, Nutrition, Exercise Elena Martinez, Tucson, AZ/USA	S23
16.20	Chemoprevention of Colorectal Cancer: Ready for Routine Use? Nadir Arber, Tel Aviv/Israel	S24
16.40	Screening of Colorectal Cancer: Progress and Problems Sidney Winawer, New York, NY/USA	S25
17.00	Discussion and Critical Session Review (E. Riboli)	
17.30	Adjourn	
19.00	“Curious Concert” with the “Kobelt-Quantett” and Dinner Reception in the Pfalz Keller (historic vaulted cellars beneath the medieval St. Gallen monastery buildings)	

Saturday, 14 February 2004

09.00–10.30	Session 9 <i>The Future of Tumor Prevention: Consens and Controversy</i> <i>Chair:</i> Peter Greenwald, Bethesda, MD/USA Peter Boyle, Lyon/France	
09.00	Overweight, Physical Activity and Cancer Prevention Inger Thune, Tromsø/Norway	S26
09.20	Endogenous Hormones and Breast Cancer Risk Paola Muti, Buffalo, NY/USA	S27
09.40	Innovative Agents in Cancer Prevention Margaret M. Manson, Leicester/UK	S28
10.00	The IARC-Commitment to Tumor Prevention Silvia Franceschi, Lyon/France	S29
10.15–10.30	Discussion and Critical Session Review	
10.30–11.00	<i>Coffee Break, Exhibition</i>	
11.00–12.30	Session 10 <i>Cancer Prevention and Health Economics: Benefits or Losses?</i> <i>Chair:</i> Th. Szucs, Basel/Switzerland Franz Porzsolt, Ulm/Germany	
11.00	Health Economics in the Genomic Age Thomas Szucs, Zürich/Switzerland	S30
11.20	Clinical Economics of Tumor Prevention: The Validity of the Program Franz Porzsolt, Ulm/Germany	S31
11.40	Modelling the Cost-Effectiveness of Cancer Screening Tests: Challenges and Opportunities Robert M. Kaplan, La Jolla, CA/USA	S32
12.00–12.20	Discussion and Critical Session Review (F. Porzsolt)	
12.20–12.30	Closing Remarks Rudolf Morant, St. Gallen/Switzerland	
12.30	Adjourn	
13.00–18.00	Appenzell Mountain Tour (departure from conference site)	